1例瑞舒伐他汀钙联合普罗布考致横纹肌溶解并急性肝肾损伤分析

doi:10.19803/j.1672-8629.2022.07.22

中国药物警戒 ›› 2022, Vol. 19 ›› Issue (7): 792-794.
DOI: 10.19803/j.1672-8629.2022.07.22

1例瑞舒伐他汀钙联合普罗布考致横纹肌溶解并急性肝肾损伤分析

陈静, 成华, 刘宪军^*

首都医科大学附属北京潞河医院,北京 101149

收稿日期:2020-08-06 出版日期:2022-07-15 发布日期:2022-07-12
通讯作者: ^*刘宪军,男,硕士,主任药师,临床药学。E-mail：13910228100@163.com
作者简介:陈静,女,硕士,主管药师,临床药学。
基金资助:
首都临床特色应用研究（Z181100001718144）

Acute liver and kidney injury due to rhabdomyolysis induced by rosuvastatin calcium tablets combined with probucol tablets

CHEN Jing, CHENG Hua, LIU Xianjun^*

Department of Medicine, Beijing Luhe Hospital, Capital Medical University, Beijing 101149, China

Received:2020-08-06 Online:2022-07-15 Published:2022-07-12

摘要/Abstract

摘要： 目的探讨瑞舒伐他汀钙联合普罗布考致横纹肌溶解并急性肝肾损伤的处置措施。方法分析1例瑞舒伐他汀钙和普罗布考联合使用后发生横纹肌溶解并急性肝肾损伤患者的诊疗经过,结合文献探讨其发生机制及应对措施。结果患者联合使用瑞舒伐他汀钙和普罗布考14 d后,出现肌酸激酶、转氨酶和血清肌酐值快速升高,立即停用2种降脂药物,积极补液、利尿并行多次血液透析后,患者肌酸激酶、转氨酶和血清肌酐值逐步下降,并于停药后34 d恢复之前水平。结论联合使用瑞舒伐他汀钙、普罗布考发生横纹肌溶解并急性肝肾损伤后,应立即停药,积极补液,必要时行血液透析。

关键词: 瑞舒伐他汀钙, 普罗布考, 横纹肌溶解, 急性肝肾损伤, 药品不良反应

Abstract: Objective To explore ways to treat rhabdomyolysis along with acute liver injury and acute kidney injury induced by rosuvastatin calcium and probucol. Methods The process of treating one case of rhabdomyolysis along with acute liver injury and acute kidney injury due to rosuvastatin calcium and probucol was analyzed based on literature review. The mechanism by which rosuvastatin calcium and probucol induced rhabdomyolysis complicated with acute liver injury and acute kidney injury was investigated. Results The patient was diagnosed with rhabdomyolysis along with acute liver injury and acute kidney injury 14 days after rosuvastatin calcium and probucol were used. These two drugs were withdrawn on the same day and the patient was given sufficient rehydration, dieresis and hemodialysis. The level of CK and indexes of the liver and kidney of the patient decreased gradually and returned to the previous level 34 days after drug withdrawal. Conclusion The use of rosuvastatin calcium and probucol should be discontinued immediately in case of rhabdomyolysis along with acute liver injury and acute kidney injury. The patient should be given active fluid rehydration and hemodialysis if it is necessary.

Key words: rosuvastatin calcium tablets, probucol tablets, rhabdomyolysis, acute liver injury and acute kidney injury, adverse drug reaction

中图分类号:

R994.11

陈静, 成华, 刘宪军. 1例瑞舒伐他汀钙联合普罗布考致横纹肌溶解并急性肝肾损伤分析[J]. 中国药物警戒, 2022, 19(7): 792-794.

CHEN Jing, CHENG Hua, LIU Xianjun. Acute liver and kidney injury due to rhabdomyolysis induced by rosuvastatin calcium tablets combined with probucol tablets[J]. Chinese Journal of Pharmacovigilance, 2022, 19(7): 792-794.

参考文献

[1] Joint committee issued Chinese guideline for the management of dyslipidemia in adults. Chinese guidelines for prevention and treatment of dyslipidemia in adults (2016 revision)[J]. Chinese Circulation Journal(中国循环杂志), 2016, 31(10): 937-950.
[2] SHI HJ, ZHANG XJ, CHEN F, et al.Clinical effect of probucol combined with atorvastatin intensive treatment on TIA caused by extracranial segment stenosis of internal carotid artery and the preventive effect on ischemic stroke[J]. Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease(实用心脑肺血管病杂志),2020, 28(3): 97-101.
[3] DENG Z, XIANG YJ.Literature analysis of 52 cases of adverse reactions of rosuvastatin[J]. Herald of Medicine(医药导报),2018(S1): 125-127.
[4] HE ZF, YANG QQ, LU YQ, et al.Acute liver injury caused by ultra-short-term use of rosuvastatin calcium[J]. ADRJ(药物不良反应杂志), 2019, 21(5): 391-392.
[5] LU XL, SONG HT, DAI HB.One case of liver injury caused by rosuvastatin calcium[J]. Herald of Medicine(医药导报), 2019, 38(1): 116-117.
[6] HUSSAIN K,XAVIER A.Rosuvastatin-related rhabdomyolysis causing severe proximal paraparesis and acute kidney injury[J]. BMJ Case Reports,2019,12(10): e229244.
[7] MADAN S, MEHRA MR.Rhabdomyolysis with the combined use of danazol and rosuvastatin in left ventricular assist devices[J]. The Journal of Heart and Lung Transplantation, 2020, 39(5): 498-500.
[8] CHEN HL, ZHAO XY, DONG Y, et al.One Case of rhabdomyolysis induced by rosuvastatin calcium combined with colchicine tablets[J]. Chinese Journal of Pharmacovigilance(中国药物警戒),2018, 15(9): 574-576.
[9] NANA IO, CILLIS M, GIZZI M, et al.Rhabdomyolysis and acute kidney injury induced by the association of rosuvastatin and abiraterone: a case report and review of the literature[J]. J Oncol Pharm Pract, 2021, 27(1): 216-219.
[10] TIAN DQ, WEI LR.One case of severe diarrhea induced by probucol[J]. Herald of Medicine(医药导报), 2008, 27(8): 1006.
[11] SUN WH, JIN ZB.One case of drug-dermatitis induced by probucol[J]. Capital Medical(首都医药), 2009, 16(24): 52.
[12] National Center for ADR Monitoring, China. Announcement of the State Food and Drug Administration on Amending the Instruction Sheet for Probucol[EB/OL]. (2020-03-13)[2020-08-01]. https://www.cdr-adr.org.cn/drug_1/aqjs_1/drug_aqjs_smssggg/202003/t20200313_47184.html.
[13] STROES ES, THOMPSON PD, CORSINI A, et al.Statin-associated muscle symptoms: Impact on statin therapy-European atherosclerosis society consensus panel statement on Assessment aetiology and Management[J]. Eur Heart J, 2015, 36: 1012-1022.
[14] LI XY, LYU Y.Influence of hypoproteinemia on the efficacy of antibiotics in critically ill patients[J]. Chin J Tubere Respir Dis(中华结核和呼吸杂志), 2018, 41(8): 600-603.
[15] WANG D, LIN F, MOU JS, et al.Clinical diagnosis and treatment of rhabdomyolysis combined with acute liver injury[J]. Journal of Critical Care in Internal Medicine(内科急危重症杂志), 2018, 24(5): 389-391.
[16] LI SJ, XU ST, GAO EZ, et al.Rhabdomyolysis induced acute kidney injury[J]. J Nephrol Dialy Transplant(肾脏病与透析肾移植杂志), 2016, 25(1): 14-19.
[17] VANHOLDER R, SEVER MS, EREK E, et al.Rhabdomyolysis[J]. JASN, 2000,11(8): 1553-1561.

1例瑞舒伐他汀钙联合普罗布考致横纹肌溶解并急性肝肾损伤分析

Acute liver and kidney injury due to rhabdomyolysis induced by rosuvastatin calcium tablets combined with probucol tablets

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	贾晋生, 刘红亮, 王青, 侯永芳, 李馨龄. 基于知识图谱联合ERNIE-DPCNN模型的药品不良反应自动关联性评价方法研究[J]. 中国药物警戒, 2024, 21(2): 163-166.
[2]	李应芬, 韩雷. 319例注射用脑蛋白水解物药品不良反应报告分析[J]. 中国药物警戒, 2024, 21(2): 195-198.
[3]	徐伟佳, 彭崎, 黄海渝, 张磊姣, 肖华, 吴雪. 285例新型抗肿瘤药物不良反应分析[J]. 中国药物警戒, 2024, 21(2): 199-203.
[4]	郭清华, 彭笑笑, 朱萍, 刘西霖, 杨颖华, 陈志海. 氨氯地平过量致多器官功能障碍综合征1例分析[J]. 中国药物警戒, 2024, 21(2): 204-207.
[5]	方美琳, 郑慧敏, 王存泽, 王凌, 阮君山. 注射用奥沙利铂致全身肌肉疼痛1例分析[J]. 中国药物警戒, 2024, 21(2): 208-210.
[6]	陈玉艳, 张明霞, 张涛, 张晋. 斯鲁利单抗注射液致间质性肺炎不良反应1例分析[J]. 中国药物警戒, 2024, 21(2): 213-215.
[7]	曹桂萍, 邓琳琳, 朱干红, 陆颖, 马爽, 陈玲玲, 刘丽丽. 天麻首乌片致严重肝损伤1例分析[J]. 中国药物警戒, 2024, 21(2): 216-218.
[8]	高云娟, 赵旭, 白天凯, 柏兆方, 王伽伯, 宋海波, 肖小河. 基于不良反应监测大数据的药品安全风险发现与识别策略[J]. 中国药物警戒, 2024, 21(1): 1-5.
[9]	郭龙鑫, 高云娟, 吴承钊, 龙敏娟, 祝胜凯, 宋海波, 赵旭, 肖小河. 基于不良反应监测大数据的中药药源性肝损伤风险信号新发现及易感因素初探[J]. 中国药物警戒, 2024, 21(1): 15-19.
[10]	蒋文硕, 杨莉. 694例癫痫医师药师联合门诊患者药品不良反应分析[J]. 中国药物警戒, 2024, 21(1): 102-106.
[11]	陈华炎, 江东波, 郭春连, 杨家琪, 黎雨欣, 蔡伟明. 326例奈玛特韦片/利托那韦片治疗新型冠状病毒感染安全性分析[J]. 中国药物警戒, 2024, 21(1): 107-110.
[12]	刘赛月, 吕小琴, 周耘. 疑似药品不良反应死亡病例调查及报告实施要点[J]. 中国药物警戒, 2023, 20(9): 971-974.
[13]	里筱竹, 王蔷, 逄瑜, 张轶菁. 个例药品不良反应报告管理浅析与思考[J]. 中国药物警戒, 2023, 20(9): 975-977.
[14]	逄瑜, 刘博, 吕少俐, 王涛, 邢颖, 秦星宇, 田月洁, 吴文宇. 基于国际药物警戒经验探讨收集患者报告的意义[J]. 中国药物警戒, 2023, 20(9): 978-981.
[15]	刘文东, 崔欢欢, 王晓晗, 苏娴, 王海学. 我国儿童用药临床试验期间药物警戒监管体系现状及思考[J]. 中国药物警戒, 2023, 20(9): 1002-1006.